Overview Technology transfer process Services Business development Marketing Patents Legal Yissum staff Researcher Area Overview Strategies Team Directors Products Companies News Events Press Releases Newsletters Picture Gallery BioMed 2009 Exhibitions Biomed 2010 Movies Computer Science Subsidiaries Yissum News 189 records page 1-10 06/09/2010 Yissum and eTeacher sign agreement for onlign university courses Hebrew U. goes global – thanks to accredited online courses with eTeacher Read More... 05/09/2010 Hebrew U. researchers develop treatment to kill HIV cells The researchers registered a patent this year on their therapy through Yissum, the Hebrew University's technology transfer body. Yissum is now seeking a commercial partner to continue developing the treatment ahead of the next phase of experimentation, on animals, and later, if its efficacy is proven, on humans. Read More... 19/08/2010 A Cure for HIV Could Be All in the 'Mix' Professors Abraham Loyter and Assaf Friedler at The Hebrew University of Jerusaleman present and innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells. This approach if successful could lead into an anti-HIV therapy that will eradicate the virus. Read More... 15/07/2010 Using GPS to track crowds and evaluate our health Using GPS technology, Israeli scientists can track our activities in space and time, spurring a seemingly infinite number of potential applications from medicine to crowd control. Read More... 25/06/2010 Potato battery could help meet rural energy needs Teo Sanchez, energy technology and policy advisor at Practical Action, a charity which promotes technology for development, said: "With half the world's population having no access to modern energy, this research is a valuable contribution to one of the biggest challenges in the world". Read More... 17/06/2010 Israeli-developed boiled potato batteries may provide cheap power An electric battery based on boiled potatoes could provide a cheap source of electricity in the developing world, according to the technology transfer company of the Hebrew University of Jerusalem. Read More... 16/06/2010 Yissum spin off Morria Biopharmaceuticals announces Promising Safety, Tolerability and Efficacy Results from MRX-4 Phase II study Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4 (n=105) in patients suffering from allergic rhinitis at the upcoming 29th EAACI Congress (European Academy of Allergy and Clinical Immunology) in London on June 7th. Read More... 10/06/2010 Yissum spin off BriefCam Among Eight Israeli firms named in Red Herring 2010 The eight Israeli companies are attracTV, BriefCam Ltd., MS Tech Ltd., SolarEdge Technologies Ltd., SundaySky, TaKaDu, Trusteer and Waze Read More... 04/06/2010 Hebrew University Looks to Commercialize Optimization Algorithm for Drug Discovery Applications Yissum, the technology-transfer arm of the Hebrew University of Jerusalem, is exploring commercialization plans for a stochastic optimization algorithm that can be used to winnow down large compound libraries to a handful of molecules with the highest probability of possessing specific drug-like characteristics. Read More... 03/06/2010 Promising Safety, Tolerability and Efficacy Results from Yissum Spin Off Morria Biopharmaceuticals' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4 (n=105) in patients suffering from allergic rhinitis at the upcoming 29th EAACI Congress (European Academy of Allergy and Clinical Immunology) in London on June 7th. Read More... 01/06/2010 Yissum Spin off Atox Bio: Time to fight septic shock Atox Bio is an Israeli Biotechnology company that develops therapeutics for diseases mediated by an excessive inflammatory response. Read More... 25/05/2010 Yissum Introduces a Breakthrough Computational Method for Superfast Drug Discovery Yissum introduces Dralgo, a novel computational platform for accelerated discovery of promising drug candidates. The new technology will be presented by its inventor, Professor Amiram Goldblum from the Institute of Drug Research at the Hebrew University of Jerusalem, on Tuesday, June 15 at the Technology Transfer Session II of the ILSI Biomed Israel 2010 conference, to be held at the David Intercontinental Hotel, Tel Aviv, Israel. Read More... 24/05/2010 Computer Algorithm Can Recognize Sarcasm The pursuit of machine intelligence means we have to come up with ways to communicate with our computers in a way both entities can understand. But while computers process verbal commands in a straightforward fashion, humans tend to use more sophisticated speech forms, employing slang or symbols to convey an idea. So an Israeli research team has developed a machine algorithm that can recognize sarcasm. Read More... 23/05/2010 YIssum spin off BriefCam Video Synopsis Wins 2010 IFSEC Security Industry Award BriefCam’s Video Synopsis – the technology that enables users to browse hours of video in minutes – was named “CCTV System Product of the Year” Read More... 21/04/2010 Yissum Licenses Cutting Edge Technology for Enhanced Digital Image Processing to Adobe Systems The technology, invented by Dr. Raanan Fattal from the Hebrew University's School of Computer Science and Engineering, is called Edge Avoiding Wavelets and it enables better and faster detail enhancement and preserves edges when sharpening digital images. Read More... 14/04/2010 Avraham Pharmaceuticals Ltd. has raised $9 million from Clal Biotechnology Industries, Yissum Technology Transfer Company of the Hebrew University of Jerusalem, the Pontifax Fund LP, Prof. Marta Weinstock-Rosin of the Hebrew University and other investors Yissum also said that, together with the Technion Research and Development Foundation (TRDF), the technology transfer arm of the Technion Israel Institute of Technology, it will exclusively license to Avraham the commercial rights of Ladostigil, a novel cholinesterase, brain-selective monoamine oxidase inhibitor and europrotective agent for treatment of Alzheimer's disease and other neurodegenerative diseases. The drug has proven to be safe and well tolerated in Phase I/IIa clinical trials. Read More... 07/04/2010 ‘Superdominant’ mutant tomato gene could spark revolution A single gene discovered by Hebrew University and US researchers Prof. Dani Zamir, Dr. Uri Krieger and Dr. Zach Lippman promises to produce tomatoes – one of Israelis’ favorite vegetables – in dramatically higher yields and with better taste. The discovery was patented by Yissum, HU’s technology transfer arm, which is seeking partners for further development and commercialization. Read More... 06/04/2010 Custom-built IP management software enhances marketing for Yissum Anew IP management software system called TTM (Technology Transfer Management), recently installed at Yissum, the tech transfer company of the Hebrew University of Jerusalem, has made a dramatic difference in the company’s marketing efforts. Read More... 21/03/2010 Yissum CEO Yaacov Michlin interview for Globes [Hebrew] "We find various ways to bridge the financial gap over the "Valley of Death": bringing our projects to a valid proof of concept." Read More... 18/03/2010 Yissum Licensee Protalix Initiates a Phase I Clinical Trial of Acetylcholinesterase for Biodefense Indications The PRX-105 program is being conducted in collaboration with Professor Hermona Soreq, from the Hebrew University in Jerusalem, Israel, a world leader in the field of acetylcholinesterase research, and based on patents that were licensed to Protalix Ltd. by Yissum. Read More... 1 2 3 4 5 |  NEXT     Advanced News Events Press Releases Newsletters Picture Gallery Movies
	All rights reserved to Yissum    |    disclaimer ICS בניית אתרים